April 4, 2022 7:53am
News: Ionis Pharmaceuticals (IONS +$0.10) partner, AstraZeneca announced positive data from the ETESIAN P2b study of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with hypercholesterolemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).
Pre-open indications: 3 SELLs, 5 BUYs and 1 pimp/pump/promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.01% (-4 points), S&P futures are UP +0.12% (+6 points) and NASDAQ futures are +0.30% (+44 points)
U.S. stock index futures were mixed and appearing flat on Monday,
European markets were mixed as Russian horror stories happening in the Ukraine,
Asia-Pacific markets were mostly higher with Hong Kong’s leading gains as markets in mainland China are closed on Monday and Tuesday this week for holidays.
Henry’omics:
Friday’s positive session came despite March’s employment report, which fell short of economists’ estimates.
An often-cited recession signal was triggered Thursday evening when the 2-year and 10-year Treasury yields inverted for the first time since 2019. The 5-year note yield is also trading above its 30-year counterpart. “We think the current flattening is due to the concern that the Fed is behind the curve on hikes and will tighten policy beyond neutral, which will hurt growth,” TD Securities said in a note to clients. <CNBC>
RegMed Investors’ (RMi) closing bell: “an uptick for the oversold. New month and quarter with the oversold cell and gene therapy sector jumping into positive territory” … https://www.regmedinvestors.com/articles/12371
Ebb and flow –
Q2/22 – 1 positive close
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... (VSTM, BCLI and ADVM) 34 total to date
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS, POSSIBILITIES and POTENTIALS …
BUY:
AVROBIO (AVRO) closed down -$0.07 after Thursday’s -$0.11, Wednesday’s -$0.09, Tuesday’s +$0.06 and last Monday’s -$0.08 with a positive +$0.05 or +4% pre-open indication.
Beam Therapeutics (BEAM) closed up +$2.65 after Thursday’s -$2.15, Wednesday’s -$2.57 and Tuesday’s +$2.97 with a positive +$2.05 or +3.42% pre-open indication.
CRISPR Therapeutics (CRSP) closed up +$3.38 after Thursday’s -$1.31, Wednesday’s -$1.87, Tuesday’s +$3.12 and last Monday’s +$0.69 with a positive +$1.30 or +1.97% pre-open indication.
Ionis Pharmaceuticals (IONS) closed up +$1.86 to $38.90 with news (above) after Thursday’s +$1.35, Wednesday’s $35.69, Tuesday’s $36.46 and last Monday’s $35.88 and a positive +$0.10 or +0.26% pre-open indication.
SELL into Strength:
Fate Therapeutics (FATE) closed up +$2.55 after Thursday’s -$1.09, Wednesday’s -$2.08 and last Tuesday’s +$3.94 with a positive +$2.38 or +5.76% pre-open indication.
Cellectis SA (CLLS) closed up =$0.31 to $4.85 with a negative -$0.07 or -1.44% pre-open indication.
Maintaining SELL:
Global Blood Therapeutics (GBT) closed up +$1.27 after Thursday’s -$0.31 and Wednesday’s -$0,54 with a negative -$0.44 or -1.23% pre-open indication
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed flat with 16 shares traded after Thursday’s -$0.10 with 124 shares traded, Wednesday’s +$0.50 with 3,932 shares traded, Tuesday’s -$0.50 with 3,330 shares traded, and last Monday’s +$0.26 to $5.00 with 13,012 shares traded. Post earning’s release …WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion?
The BOTTOM LINE: I think and feel even if not today, the cell and gene therapy sector is in the midst of a yet another slow pullback.
It is all dependent on the stock market rally run-up through, breaking past fresh resistance levels. Then the major indexes pulled back, with the Nasdaq stopping short of the 200-day line.
Is this a signal for a return of sector rotation or just a narrow rally?
Reiterating, keep positions small and diversified amid modest overall exposure to limit any fallout. Taking profits quickly and cutting losers quickly is still vital
Reiterating, “An odd quote that caught my eye and some feelings, “To paraphrase the Rolling Stones, you can't always get what you want, but sometimes you get what you need.”
Again, I reiterate, “I’m never totally wrong but, not always wholly right as there is no clear trend ….
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
